Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Yeast on the brain

How Yumanity's platforms allow it to uncover novel neurology targets

Steve Edelson, Senior Editor
April 25, 2016 7:00 AM UTC

Yumanity Therapeutics LLC is using an iterative loop of phenotypic screens to tackle diseases caused by misfolded proteins. The company, led by veteran biotech executive Tony Coles and backed by investors with long-term horizons, is focused on Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.

Coles founded Yumanity in 2014 along with Susan Lindquist. Coles was chairman, president and CEO of Onyx Pharmaceuticals Inc., which Amgen Inc. acquired for $10.4 billion in 2013. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article